AM Best Affirms Credit Ratings of Elevance Health, Inc. and Its Subsidiaries

Rhea-AI Summary

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and various credit ratings for Elevance Health Inc. (NYSE: ELV) and its subsidiaries. The outlook for all ratings remains stable. The affirmations reflect Anthem Health's very strong balance sheet, strong operating performance, and favorable business profile.

Key highlights include a 5-year compound annual capital growth rate of 8%, outpacing premium growth of 6.8%. The company maintains a conservative investment portfolio and sound liquidity with access to $4 billion in credit facilities. Financial leverage increased to 42% due to recent debt issuance but is expected to return to the 40% range by 2025.

Despite challenges in Medicaid membership due to state redeterminations, Elevance maintains strong profitability ratios and operates BCBS plans in 14 states with significant market presence.

Positive

• Strong balance sheet with 8% compound annual capital growth rate
• Access to $4 billion in credit facilities showing solid liquidity
• Consistent premium growth and solid earnings across operations
• Leading market share in majority of BCBS states
• Very strong risk-adjusted capitalization (BCAR)

Negative

• Financial leverage increased to 42% due to new debt issuance
• High goodwill and intangibles to equity ratio (over 80%)
• Declining Medicaid membership due to state redeterminations
• Lower ERM sophistication compared to peers

Insights

Financial Analyst

The AM Best rating affirmation of Elevance Health's A (Excellent) FSR and "a+" ICR reflects strong fundamentals and market position. Key positives include very strong balance sheet strength, 8% five-year compound annual capital growth outpacing premium growth of 6.8% and conservative investment portfolio. While financial leverage increased to 42% due to recent debt issuance, it's expected to moderate to the 40% range by 2025. The company maintains solid liquidity with access to $4 billion in credit facilities. However, high goodwill and intangibles at over 80% of equity warrant monitoring. Strong operating performance continues despite Medicaid membership challenges from ongoing eligibility redeterminations.

Market Research Analyst

Elevance Health maintains a dominant competitive position through its BCBS operations across 14 states plus non-Blue branded presence in 12 additional states via AMERIGROUP. The company's strategic diversification into pharmacy benefits management, complex care and behavioral health creates operational synergies and competitive advantages. Geographic expansion through targeted M&A strengthens market penetration while building non-regulated capabilities. Strong brand recognition and leading market share in BCBS territories, combined with growing individual exchange product offerings, position the company well for continued growth despite near-term headwinds in Medicaid enrollment.

OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a+” (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) [NYSE: ELV], as well as its life insurance subsidiaries. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of “bbb+” (Good), the Long- and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of Elevance and the Long-Term IR on the existing surplus notes of Anthem Insurance Companies, Inc. (Indianapolis, IN).

In addition, AM Best has affirmed the FSR of A- (Excellent) and the Long-Term ICR of “a-” (Excellent) of the members of WellPoint Life & Health Group (WellPoint), a subsidiary of Elevance.

Lastly, AM Best has affirmed the FSR of A- (Excellent) and the Long-Term ICR of “a-” (Excellent) of WellPoint Insurance Services, Inc. (WISI) (Honolulu, HI). The outlook of all these Credit Ratings (ratings) is stable.

The ratings of Anthem Health reflect the group’s balance sheet strength, which AM Best assesses as very strong, as well as its strong operating performance, favorable business profile and appropriate enterprise risk management (ERM).

Anthem Health’s rating affirmations reflect its very strong balance sheet strength, which has been driven by the group’s favorable operating performance and strong cash flow trends. The group’s risk-adjusted capitalization is considered very strong, as measured by Best’s Capital Adequacy Ratio (BCAR). Furthermore, Anthem Health has continued to report consistent capital and surplus growth, driven by favorable net earnings, which has outpaced premium growth consistently and led to increased absolute and risk-adjusted capitalization. The group’s five-year compounded annual capital and surplus growth rate was close to 8%, outpacing compounded annual net premium written of 6.8% through the most recent year end. Anthem Health’s invested asset portfolio has been relatively conservative and mainly composed of investment grade fixed income securities, cash and short-term investments, as well as minor allocations to alternative invested assets.

AM Best recognizes that Anthem Health's current level of liquidity was sound through 2024. The group has access through its holding company to a $4 billion revolving credit facility and a $4 billion commercial paper program (with a combined maximum of $4 billion capacity to borrow between the two programs). Anthem Health also has access to Federal Home Loan Bank (FHLB) program borrowings through its insurance subsidiaries. There were approximately $360 million FHLB borrowings outstanding as of September 2024.

Anthem Health’s financial leverage at Elevance increased to approximately 42% due to new debt issuance in October 2024. However, AM Best expects financial leverage to moderate slightly by year-end 2024 driven by merger and acquisition activities. AM Best expects Elevance’s financial leverage to return to the 40% range by the end of 2025. Moreover, Elevance has been active in small and mid-sized acquisitions over the past years, expanding its presence in various insurance markets and building stronger nonregulated and vertical integration capabilities. However, while financial leverage remains within acceptable range, AM Best considers Elevance’s goodwill and intangibles to equity as high, at over 80% through September 2024. AM Best acknowledges that a portion of the intangibles is the BCBS trademarks, which are required to operate as a BCBS-branded entity. Furthermore, Elevance has demonstrated strong interest coverage through 2024. Cash flows from its regulated and nonregulated operations also have been very good and generally increased over the past five years.

Anthem Health’s operating performance is considered strong, with the company reporting consistent premium growth and solid earnings, although some lines of business will remain challenged for the remainder of 2024 and throughout 2025. Premium growth has been driven by enrollment gains in most of its lines of business. The company’s operating earnings benefit from its sizeable overall membership and the related economies of scale, which benefits its medical expenditures and administrative expenses metrics. However, the company’s Medicaid membership has declined with the advent of state redeterminations of eligibility commencing in 2023 and continuing into 2024, driving declines that have offset growth from new contracts. Although investment income is positive, it contributes modestly to overall net earnings. Profitability ratios remain strong, as measured by its return-on-revenue and return-on-equity metrics through 2024.

Anthem Health’s vast and diversified product offerings remain the basis for its favorable business profile. The group has good geographic diversity, as Elevance operates BCBS plans in 14 states, as well as its non-Blue branded with CareMore, AMERIGROUP and WellPoint entities. Anthem Group continues to benefit from strong brand name recognition and a leading market share in the majority of these BCBS states. Additionally, the Elevance companies have a strong presence in the national account/BlueCard market segment and there has been a significant expansion of individual exchange product offerings over the past few years. AMERIGROUP entities operate in an additional 12 states in the Managed Care Medicaid segment, further expanding Anthem Health’s footprint. In addition, various nonregulated business in the Anthem organization, including pharmacy benefit management, complex and home care management and behavioral health administration, add a competitive advantage in all lines of business and allow for cost efficiencies.

Moreover, Anthem Health’s ERM is managed at the ultimate parent level, but it has local functionality as well. The ERM program is well-established and is coordinated at the corporate level. Elevance’s ERM is considered appropriate for its risk profile but has a lower level of sophistication when compared with some of its peers. Risk identification and reporting are completed on a regular basis, and ERM is incorporated into the corporate strategic planning. There is established oversight and monitoring of the ERM program.

The ratings of WellPoint reflect its balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, limited business profile and appropriate ERM. The ratings also factor in the support of its parent. Over the years, WellPoint entities have been assuming a large volume of Medicaid premium from various Elevance affiliates. Most recently, WellPoint terminated a couple of contacts, which is expected to have some impact on its overall operations in the near term.

Furthermore, the ratings of WISI reflect its balance sheet strength, which AM Best assesses as adequate, as well as its adequate operating performance, limited business profile and appropriate ERM. In addition, the ratings also factor in WISI’s strategic importance to the parent.

WISI’s rating affirmations reflect its risk-adjusted capitalization at the strongest level at year-end 2023, as measured by BCAR, driven mainly by an improved capital position. WISI’s capital growth was supported by its consistent positive earnings and no dividends to the parent company through third-quarter 2024. Elevance has demonstrated explicit and implicit support of WISI in past years. WISI benefits from the parent’s operational resources and expertise. WISI’s importance to the parent has increased in recent years as the volume of business in the core and the cell has expanded.

WISI is a Hawaii-domiciled captive and a wholly owned subsidiary of Elevance. WISI was established nearly two decades ago primarily for the purpose of formalized self-insurance and an instrument of corporate risk management. In the past several years, Elevance expanded the volume of excess managed care errors and omission (E&O) coverage placed with WISI as the market for this line of business has hardened considerably. In addition, WISI established a segregated cell to assume Federal Employees Health Benefits Program (FEP) premium from Elevance affiliates to optimize capital at statutory entities a few years ago. Furthermore, the cell structure provides a formal separation of FEP from other WISI businesses, provides transparency for Hawaii’s regulators and allows for potential future WISI expansion into assuming other health lines. WISI’s core operations in the protected cell – FEP premiums – continue to drive revenue and earnings for the company. The core corporate insurance lines of business – workers’ compensation and E&O – have posted fluctuating operating results, including lower operating losses over the past couple of years. These results have been driven in part by fluctuations in claims severity and increases in coverage limits, which resulted in the need for reserve strengthening in recent years. WISI expects the consolidated financial performance of the company to be stable in the current year.

A complete listing of Elevance Health, Inc.’s FSRs, Long-Term ICRs and Long-Term IRs also is available.

AM Best remains the leading rating agency of alternative risk transfer entities, with more than 200 such vehicles rated in the United States and throughout the world. For current Best’s Credit Ratings and independent data on the captive and alternative risk transfer insurance market, please visit www.ambest.com/captive.

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2024 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241211128881/en/

Jennifer Asamoah

Senior Financial Analyst

+1 908 882 1637

jennifer.asamoah@ambest.com

Joseph Zazzera

Director

+1 908 882 2442

jospeh.zazzera@ambest.com

Christopher Sharkey

Associate Director, Public Relations

+1 908 882 2310

christopher.sharkey@ambest.com

Al Slavin

Senior Public Relations Specialist

+1 908 882 2318

al.slavin@ambest.com

Source: AM Best

FAQ

What is Elevance Health's (ELV) current Financial Strength Rating from AM Best?

AM Best has affirmed Elevance Health's Financial Strength Rating (FSR) of A (Excellent) for its core Blue Cross Blue Shield-branded insurance subsidiaries.

What is ELV's current financial leverage ratio and future outlook?

Elevance Health's financial leverage increased to 42% in October 2024 due to new debt issuance, but AM Best expects it to return to the 40% range by the end of 2025.

How has Elevance Health's (ELV) capital growth performed over the past five years?

Elevance Health achieved a five-year compound annual capital and surplus growth rate of 8%, outpacing its net premium written growth of 6.8%.

What is the impact of Medicaid redeterminations on ELV's membership?

Elevance Health has experienced declining Medicaid membership due to state redeterminations of eligibility that commenced in 2023 and continued into 2024.

What credit facilities does Elevance Health (ELV) have access to?

Elevance Health has access to a $4 billion revolving credit facility and a $4 billion commercial paper program, with a combined maximum borrowing capacity of $4 billion between the two programs.